Nestlé Skin Health and Palette Life Sciences have entered into a global licensing agreement intended to improve outcomes for patients with urological and colorectal disorders.
After spending four years at Hughes Hubbard & Reed, Stephen Rabinowitz has joined Dechert’s New York office as a partner.
The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.
ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
The US Court of Appeals for the Federal Circuit has upheld two decisions that said patents relating to the dosage of Teva’s Copaxone 40mg/mL treatment are invalid.
Nestlé’s Skin Health unit has been accused of infringing patents and misappropriating trade secrets relating to neurotoxin and derma filler injections.
AbbVie has announced yet another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.
Eli Lilly has filed a complaint against France-based biotechnology company Adocia over patents relating to fast-acting insulin.
Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.
The US Food and Drug Administration has released guidance intended to advance the development of generic versions of complex medical drugs.